For oral immediate-release tablet manufacture in which 4-amino-5-imidazolecarboxamide hydrochloride is the active moiety, direct compression is initiated only after a powder rheology screen carried out per USP <1174> and USP <429>. The salt is milled through a comil fitted with a 0.5 mm rasp screen at 1200 rpm; particle-size acceptance before blending is D90 ≤ 150 µm and D50 75–120 µm. Published compaction data for this specific imidazolecarboxamide hydrochloride salt are limited; therefore a compaction simulator study is run at 0.1–100 kN to establish tabletability and to detect heel compression above 80 kN. A representative direct-compression matrix may comprise microcrystalline cellulose PH102 and anhydrous lactose in equal parts, croscarmellose sodium at 2.0% w/w, colloidal silicon dioxide at 0.5% w/w, and magnesium stearate at 1.0% w/w. The API, filler, and disintegrant are blended in a 300 L bin blender at 8–12 rpm for 15 min; magnesium stearate is passed through a 600 µm screen and blended for no more than 180 s because extended lubrication above 5 min can form hydrophobic films that slow dissolution below Q=80% at 30 min in USP <711> Apparatus II at 50 rpm in 900 mL of 0.01 N hydrochloric acid. Tablet compression is run on a rotary press with D-tooling, 8 mm round biconvex punches, precompression force 5 kN, main compression force 12–18 kN, and press speed 40–80 rpm. In-process hardness is held at 50–90 N, thickness at 3.0–3.4 mm, friability below 0.8% per USP <1216>, and weight variation per USP <905> with acceptance value ≤ 15.0. The compressed cores are film-coated with an aqueous Opadry II dispersion at 3–5% w/w weight gain in a perforated pan coater with inlet air 45–55°C, bed temperature 38–42°C, spray rate 8–12 g/min, and pan speed 8–12 rpm. Final moisture after coating is controlled at ≤ 2.0% w/w by Karl Fischer titration per USP <921> Method Ic. Residual solvents from any organic granulating solvent are controlled under ICH Q3C Class 3 limits; elemental impurities are tested by ICP-MS per USP <233> under ICH Q3D. The terminal product is an immediate-release film-coated tablet whose label claim is set by the approved dossier.

What Controls Powder Segregation During Low-Fill-Weight Capsule Filling?

When the hydrochloride API is filled into hard gelatin capsules at a fill weight below 100 mg or an API content below 10 mg per capsule, untreated API added directly to the hopper frequently produces blend uniformity relative standard deviation above 5% because of particle size differences between the API and excipients. A trituration pre-blend is therefore prepared at a 1:5 ratio with lactose monohydrate having D50 80 µm, passed twice through a 500 µm hand screen or a low-shear tumble mixer. The final blend is mixed in a double-cone blender at 12 rpm for 20 min, and lubrication with 0.5% w/w magnesium stearate is limited to 3 min. Capsule filling is performed on a tamping pin machine at 80,000–100,000 capsules/h or on a dosator machine where particle size and flow allow. Fill weight is monitored gravimetrically every 15 min and controlled to ±3% RSD; content uniformity is tested by USP <905> with an acceptance value ≤ 15.0. Dissolution is run per USP <711> Apparatus II at 50 rpm in 900 mL of 0.01 N HCl at 37 ± 0.5°C with Q=80% at 30 min for immediate-release grade. The hard gelatin shell is stored at 13–16% moisture and 40–45% RH; lower humidity causes brittle shells, and higher humidity causes shell deformation. Formaldehyde contamination is avoided because cross-linked gelatin can delay rupture and cause dissolution failure. For low-dose capsules, the analytical method must achieve limit of quantitation no greater than 0.5% of label claim to detect blend fluctuations. The terminal product is a size 3 or 4 hard gelatin capsule, printed with product identity, containing a white to off-white powder blend.

High-Shear Wet Granulation Endpoint Control for Immediate-Release Tablets

When the API cannot be processed by direct compression due to poor compactability or high drug load, high-shear wet granulation is used in a vertical granulator equipped with a 600 L bowl, main impeller at 150–250 rpm, and side chopper at 1500–2500 rpm. A binder solution of povidone K30 is prepared at 5% w/w in purified water; binder addition is 20–30% w/w of dry blend. The wet massing endpoint is determined by a 20–30% rise in impeller torque or power consumption from the dry blend baseline; granule median diameter after wet massing is typically 150–250 µm. The wet granules are dried in a fluid-bed dryer with inlet air at 60–65°C until loss on drying is 1.0–2.0% w/w by USP <731>. Dried granules are milled through a 1.0 mm conidur screen at 800 rpm; fines below 75 µm are limited to 25% to avoid capping. Final granule blend is compressed on a high-speed rotary press at 60,000 tablets/h with precompression 5 kN, main compression 12–20 kN, and ejection force below 1500 N. Tablet hardness is maintained at 70–110 N, friability ≤ 0.8% per USP <1216>, and disintegration ≤ 15 min per USP <701>. If the hydrochloride salt is found to be hygroscopic by dynamic vapor sorption with mass gain above 2% at 60% RH, drying and compression rooms are maintained at 35–40% RH. Near-infrared moisture monitoring at 1650–1750 cm⁻¹ may be used as a process analytical technology alternative, with Karl Fischer verification every 15 min. The terminal product is an immediate-release film-coated tablet, oval, debossed, and packed in high-density polyethylene bottles with desiccant.

For the injectable route, 4-amino-5-imidazolecarboxamide hydrochloride is dissolved in Water for Injection at a concentration fixed by the approved regulatory dossier; the solution is chilled to 8–15°C before sterile filtration through a 0.22 µm PVDF membrane with a polyethersulfone prefilter. Terminal steam sterilization at 121°C for 15 min per FDA 21 CFR 211.113 is preferred when heat-stability data support it; where the API degrades by more than 1% under forced degradation at 121°C, aseptic filtration and lyophilization are used instead. A representative lyophilization cycle uses freezing at -45°C shelf for 2 h, primary drying at -15°C shelf and chamber pressure 100–150 µbar for 40 h, and secondary drying at 35°C shelf for 6 h; collapse temperature is confirmed by freeze-dry microscopy before scale-up. Tonicity is adjusted with sodium chloride to 0.9% w/v or with mannitol as a bulking agent at 5% w/v. The finished solution is filled into USP Type I borosilicate glass vials of 5 mL nominal volume with chlorobutyl rubber stoppers under nitrogen overlay to reduce headspace oxygen. Filter integrity is tested before and after filtration by bubble point per ASTM F838-20. Particulate matter is tested by USP <788> Method 1 light obscuration with limits of 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container; visible particulates are inspected per USP <790>. Bacterial endotoxins are limited according to USP <85> using K=5 EU/kg for parenteral products; sterility is confirmed by USP <71> with no growth after 14 days. Residual moisture in the lyophilized cake is controlled at ≤ 2.0% w/w by USP <921> Method I. Container closure integrity is verified by USP <1207> vacuum decay. The hydrochloride salt should not be exposed to pH higher than 7.0 before filtration because the free base may precipitate and reduce diffusion flux through the sterile filter. The terminal product is a lyophilized plug in a Type I glass vial with a flip-off aluminum seal, reconstituted with 5 mL Water for Injection immediately before administration.

Compendial control matrix used across the four dosage-form pathways:

When Oral Granules Are Packed in Single-Dose Sachets

When oral granules in single-dose sachets are selected as the terminal product, the API is wet-granulated with a diluent system of sucrose or mannitol and low-substituted hydroxypropylcellulose at 5–10% w/w as binder-disintegrant. Granulation is performed in a high-shear or fluid-bed granulator; granule D50 is controlled at 200–300 µm, and fines below 75 µm are limited to 15%. If the hydrochloride salt has objectionable taste, a fluid-bed taste-masking coat of ethylcellulose or Eudragit EPO at 5–8% weight gain is applied at product temperature 30–35°C. The coated granules are lubricated with 0.2% w/w talc and filled into aluminium/polyethylene sachets at a fill weight of 500 mg to 2000 mg, adjusted to the approved dose. Fill weight is checked every 15 min and held to ±5% RSD; moisture is controlled at ≤ 2.0% w/w by USP <731>. Dispersibility is tested by transferring the sachet contents to 50 mL water at 25°C; dispersion should occur within 2 min without particles larger than 180 µm. Dissolution from the granule is tested by USP <711> Apparatus II in 900 mL of 0.01 N HCl at 50 rpm with Q=80% at 30 min. Storage is in aluminium foil sachets with desiccant if dynamic vapor sorption shows moisture uptake above 2% at 60% RH. Compliance includes FDA 21 CFR 211.110 in-process controls, ICH Q1A(R2) stability, and ICH Q3D elemental impurities. The terminal product is a single-dose oral granule sachet that may be dispersed in water or taken directly as directed by the approved product label.